VivoSeq
Oncology

Cancer-Related Pain

1

Pipeline Programs↗

3

Active Trials↗

3

Companies Involved↗

Cancer-related Pain is an early-stage landscape with 1 program across 3 companies. The most active players are Wex Pharmaceuticals Inc., Johnson & Johnson, RECORDATI GROUP.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

80/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

W

Wex Pharmaceuticals Inc.

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalR

RECORDATI GROUP

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Lidocaine

MEDRx USA, Inc.

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

8

clinical trials

Completed4 · 50%
Recruiting3 · 38%
Terminated1 · 13%

Clinical Trials

Trial Activity

8 trials

Optimizing Subcutaneous FEntanyl titRation: RApid Achievement of Adequate Exposure When Treating Cancer-Related paIn.
Recruiting·EErasmus Medical Center·Phase 4·NCT06498037·45 enrolled
Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial
Recruiting·MM.D. Anderson Cancer Center·Phase 3·NCT06200181·87 enrolled
The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain: a Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Trial.
Recruiting·NNational and Kapodistrian University of Athens·Phase 1·NCT07408193·24 enrolled
Safety & Efficacy Study of Subcutaneous Tetrodotoxin for Moderate to Severe Inadequately Controlled Cancer-related Pain
Completed·WWex Pharmaceuticals Inc.·Phase 3·NCT00725114·165 enrolled
Subcutaneous Lidocaine For Cancer-Related Pain
Completed·BBritish Columbia Cancer Agency·Phase 2/3·NCT01384877·33 enrolled
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT00929188·100 enrolled
Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids.
Completed·RRECORDATI GROUP·Phase 3·NCT01793480·146 enrolled
Methadone Versus Morphine for Cancer-Related Pain
Terminated·MMayo Clinic·Phase 2·NCT00573937·1 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)